Welcome to our dedicated page for Medirom Healthcare Technologies SEC filings (Ticker: MRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MEDIROM Healthcare Technologies Inc. filings document a foreign private issuer that reports to the SEC on Form 6-K and annual reports under Form 20-F. The company’s disclosures cover its Japan-based wellness salon operations, digital preventive healthcare products, ADR/ADS voting materials, and current reports furnished for press releases and material corporate events.
MRM filings include ordinary general meeting notices and proxy cards for common share and American Depositary Share holders, convertible-type corporate bond issuances under Japanese law, loan and maturity-extension agreements, registration statement incorporation references, KPI reporting changes, and partnership updates for World ID, Orb authentication, MOTHER Bracelet and REMONY. These records also describe capital structure, governance procedures, financing terms, risk language and foreign-issuer reporting mechanics.
MEDIROM Healthcare Technologies Inc. (MRM) amendment updates beneficial ownership and related disclosures for CEO Kouji Eguchi and COZY LLC. Mr. Eguchi is reported to beneficially own 2,075,003 Common Shares, representing 25.77% of the class using an adjusted share base; COZY LLC beneficially owns 47,543 Common Shares (0.60%). The filing attributes the percentage change to the issuer issuing additional ADSs on December 11, 2024 rather than purchases by the reporting persons. The filing discloses that Mr. Eguchi holds stock options exercisable for 150,000 shares within 60 days and an additional 36,500 options subject to revenue targets. The amendment notes the joint filing, acquisitions by COZY since the original Schedule 13D, a transfer of 7,500 shares by Mr. Eguchi in June 2025, and that this Amendment No. 1 was filed late.
Healthcare Technologies Inc. submitted a Form 6-K to inform investors that it issued a press release on a regulatory milestone in Japan. The release explains that a product developed by its subsidiary, MOTHER Labs Inc., has received certification in connection with a governmental subsidy program in Japan. This type of certification can help support adoption of the product by making it eligible for public support, though specific financial terms are not described here. The full details are provided in the attached press release, which is included as Exhibit 99.1.
MEDIROM Healthcare Technologies Inc. submitted a Form 6-K reporting that it is issuing a press release about the expected introduction of a new technological device at certain relaxation salon locations and related plans regarding digital assets. The press release is furnished as Exhibit 99.1 and is provided for informational purposes under the Exchange Act, without being treated as filed for liability purposes or automatically incorporated into other securities law filings.
MEDIROM Healthcare Technologies Inc. furnished a Form 6-K to inform investors that it is issuing a press release with updated major key performance indicators (KPIs) for the month of July 2025. The press release, dated August 20, 2025, is attached as Exhibit 99.1.
The submission clarifies that the information in this report, including the exhibit, is furnished rather than filed and is not automatically incorporated by reference into other securities law filings unless specifically stated there.
MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) submitted a routine Form 6-K on 20 June 2025. The filing simply furnishes—rather than files—a press release (Exhibit 99.1) that updates the Company’s Key Performance Indicators (KPIs) for May 2025. Because the information is “furnished,” it is not subject to Section 18 liability and will not be automatically incorporated by reference into other SEC documents. No financial statements, earnings results, or transaction details are included, and the Company confirms it continues to report under Form 20-F.